scholarly journals A Case of an Acquired Factor VIII Inhibitor Complicated by Multiple Treatment-Related Opportunistic Infections and Review of the Literature

2013 ◽  
Vol 2013 ◽  
pp. 1-4
Author(s):  
Anna L. Hutchinson ◽  
Yi Ling Tan ◽  
Giselle Kidson-Gerber

This case report describes a patient with an idiopathic acquired Factor VIII inhibitor and severe bleeding. She was treated with rituximab after failing first-line treatment with steroids and cyclophosphamide. Two months following rituximab treatment, our patient developed a succession of severe opportunistic infections requiring intensive care unit admission. Over a period of 12 weeks she required treatment forPseudomonas aeruginosasepticaemia, herpes simplex gingivostomatitis and pharyngotonsillitis, clostridium difficile-related diarrhoea, systemic cytomegalovirus infection, pneumocystis jiroveci, and invasive pulmonary aspergillosis lung infections. After significant rehabilitation, the patient was finally discharged following a 5-month admission. This case highlights the complexity of balancing a life-threatening condition with the side effects of treatment. It also raises the issue of routine prophylaxis for immunosuppression in nonmalignant conditions, which will become a common dilemma with the expanding indications for rituximab use.

2000 ◽  
Vol 11 (8) ◽  
pp. 401-405
Author(s):  
Takayuki Karino ◽  
Hanae Nakashima ◽  
Yasuhiro Fujinaga ◽  
Jun Tanabe ◽  
Niro Okimoto

2012 ◽  
Vol 32 (S 01) ◽  
pp. S75-S78 ◽  
Author(s):  
C. Niekrens ◽  
K.-W. Sykora ◽  
C. Wermes

SummaryHere, we report about a boy (age: 18 years) who developed an acquired factor VIII inhibitor at the age of 9 years. He presented with bleeding in his right ankle, multiple haematomas and a high-titer factor VIII type II inhibitor (400 BU). Therapy: He received treatment with MMF (CellCept→), dexamethasoneimmunoglobulin pulses, and rituximab together with high dose FVIII (Hannover protocol). His inhibitor titer decreased rapidly, and half-life and recovery normalized. Inhibitor titres increased after reduction of the factor VIII dose, and increased further after MMF was stopped. A second treatment course with MMF again resulted in reduction of the titre, improvement in half life and recovery, and no more bleedings. Inhibitor reappeared with MMF dose reduction, again accompanied by severe bleeding. Additional rituximab stopped the bleedings, and treatment with MMF has been continued since. Conclusion: Although the laboratory parameters showed no complete remission, severe bleedings and expensive factor replacement could be avoided by long-term treatment with MMF.


1991 ◽  
Vol 85 (3) ◽  
pp. 153-155 ◽  
Author(s):  
Takashi Okamura ◽  
Yasuo Yamauchi ◽  
Takahiro Fukuda ◽  
Kazuhisa Suehiro ◽  
Masahiro Murakawa ◽  
...  

Haemophilia ◽  
2003 ◽  
Vol 9 (5) ◽  
pp. 642-645 ◽  
Author(s):  
A. Klukowska ◽  
P. Łaguna ◽  
A. Obitko-Płudowska ◽  
K. Niedzielska ◽  
I. Malinowska ◽  
...  

2014 ◽  
Vol 37 (1) ◽  
pp. 139-141
Author(s):  
H.-W. Ip ◽  
C.-C. So ◽  
Y.-Y. R. Leung ◽  
J.-Y. Chan ◽  
P. Sin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document